Aptinyx

76 articles with Aptinyx

• Aptinyx Reports First Quarter 2021 Financial Results and Highlights

  5/13/2021

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2021 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.

• Aptinyx Appoints Joan W. Miller, M.D. to Board of Directors

  5/10/2021

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company’s Board of Directors.

• Aptinyx Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD at Society of Biological Psychiatry Annual Meeting

  4/29/2021

  Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry (SOBP) Annual Meeting being held virtually April 29 - May 1, 2021.

• Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

  4/29/2021

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that the company will host a conference call and live webcast on Thursday, May 13, 2021 at 5:00 p.m. ET to report first quarter 2021 financial results and discuss recent business highlights.

• Aptinyx to Participate in Upcoming Conferences

  4/27/2021

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the Company will be participating in two upcoming conferences: 4 th Annual Neuroscience Innovation Forum – Norbert Riedel, Ph.D., chief executive officer, will participate in the Pain & Addiction Panel discussion at 11:30 a.m

• Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies

  4/6/2021

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with Lewy bodies.

• Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  3/24/2021

  Phase 2 studies in fibromyalgia and painful DPN enrolling as planned – data readouts expected in 1H 2022 Phase 2 study in cognitive impairment expected to recommence imminently – data readout expected in 2H 2022 Reported data from Phase 2 exploratory study of NYX-783 in PTSD, supporting further clinical development – meeting with FDA to discuss future development path April 29, 2021

• Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021

  3/2/2021

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 24, 2021 at 5:00 p.m. ET to report fourth quarter and full year 2020 financial results

• Aptinyx to Participate in Upcoming Investor Conferences

  2/22/2021

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences:

• Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference

  2/11/2021

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that company management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 10:40 a.m. EST.

• Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions

  1/19/2021

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the publication of a recent review article in Medicine in Drug Discovery featuring data on its novel NMDA receptor modulator, NYX-2925.

• Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference

  1/5/2021

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, 2021. The fireside chat will be available on-demand through the H.C. Wainwright conference portal, beginning at 6

• Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference

  12/21/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will present virtually at the 39th Annual J.P. Morgan Healthcare Conference.

• Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer

  12/16/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Andy Kidd, the company’s current chief operating officer, to the role of president and chief operating officer, effective December 14, 2020.

• Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights

  11/12/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2020 and highlighted recent progress across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

• Aptinyx to Participate in Upcoming Virtual Investor Conferences

  11/10/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences

• Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020

  10/29/2020

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, November 12, 2020 at 5:00 p.m. ET to report third quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please

• Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option - Oct 26, 2020

  10/26/2020

  Aptinyx Inc. announced the closing of its public offering of 16,100,000 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share.

• 

  Clinical Catch-Up: October 19-23

  10/26/2020

  It was another busy week for clinical trial updates and news. Here’s a look.

• Aptinyx Announces Pricing of Public Offering of Common Stock - Oct 22, 2020

  10/22/2020

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $3.00 per share.